Skip to content

Depression: all studies

Page 724 of 1,034: studies 7,231 to 7,240 of 10,336, newest first. Back to the depression overview

Research

The Effects of Clinical Meditation Programs on Stress and Well-Being

Zeitschrift für Psychologie February 1, 2023 Julia Seekircher, Tanja Burgard, M. Bošnjak

Abstract. Many people suffer from chronic conditions, such as cancer, diabetes, or depression. The use and development of meditation interventions to offer complementary psychological treatment for such patients is increasing, as is criticism of research on this topic. Therefore, the aim of the present rapid review and meta-analysis is to investigate the effects of meditation interventions in...

Moderators and Nonspecific Predictors of Treatment Benefits in a Randomized Trial of Mindfulness-Based Stress Reduction vs Cognitive-Behavioral Therapy vs Usual Care for Chronic Low Back Pain.

Journal of Pain February 2023 Jessica A Chen, Melissa L Anderson, Daniel C Cherkin et al.

Both mindfulness-based stress reduction (MBSR) and cognitive-behavioral therapy (CBT) are effective for chronic low back pain (CLBP), but little is known regarding who might benefit more from one than the other. Using data from a randomized trial comparing MBSR, CBT, and usual care (UC) for adults aged 20 to 70 years with CLBP (N = 297), we examined baseline characteristics that moderated...

DOI: 10.1016/j.jpain.2022.09.014 (opens in new tab) Full text (opens in new tab) Chronic back pain Cognitive-behavioral therapy Mindfulness-based stress reduction Predictors +1

Two Cases of Dextromethorphan Overdose Reversed by Naloxone

Cureus February 1, 2023 Dhruva Kumar, V. Shinde, Sweta Khuraijam et al.

We present two rare cases highlighting the rare toxicological manifestation of dextromethorphan (DXM). The DXM toxicity profile is predominantly hallucinations, agitation, irritability with seizures, and coma in severe overdose. The cases that follow are unique in the sense that both patients had features of opioid toxidrome, rarely manifested in DXM abuse. A young male and female in their...

Intraoperative Low-Dose S-Ketamine Reduces Depressive Symptoms in Patients with Crohn’s Disease Undergoing Bowel Resection: A Randomized Controlled Trial

Journal of Clinical Medicine February 1, 2023 Zhen Zhang, Wen-Hao Zhang, Yin Lu et al.

Background: Patients with Crohn’s disease (CD) undergoing bowel resection often suffer from depression and acute pain, which severely impairs their recovery. We aimed to investigate the effects of S-ketamine preconditioning on postoperative depression in patients with CD undergoing a bowel resection with mild to moderate depression and to observe whether it can relieve postoperative pain and...

Effects of ketamine optical isomers, fluoxetine and naloxone on timing in differential reinforcement of low-rate response (DRL) 72-s task in rats.

European Neuropsychopharmacology February 2023 Natalia Malikowska‐racia, Joanna Gołębiowska, Agnieszka Nikiforuk et al.

(S)-ketamine-induced rapid-acting antidepressant effects have revolutionized the pharmacotherapy of major depression; however, this medication also produces psychotomimetic effects such as timing distortion. While (R)-ketamine produces fewer dissociative effects, its antidepressant actions are less studied. Depression is associated with time overestimation (i.e., subjectively, time passes...

Differentially regulated targets in the fast-acting antidepressant effect of (R)-ketamine: A systems biology approach.

Pharmacology, Biochemistry, and Behavior February 2023 Ellen Scotton, Pedro Lenz Casa, Fernanda Pessi De Abreu et al.

Approximately two-thirds of patients with major depressive disorder (MDD) fail to respond to conventional antidepressants, suggesting that additional mechanisms are involved in the MDD pathophysiology. In this scenario, the glutamatergic system represents a promising therapeutic target for treatment-resistant depression. To our knowledge, this is the first study using semantic approach with...

DOI: 10.1016/j.pbb.2023.173523 (opens in new tab) Full text (opens in new tab) R-ketamine Glutamatergic synapse Ketamine enantiomers Molecular targets +2

Mindfulness and Chronic Musculoskeletal Pain: An Umbrella Review

Journal of Multidisciplinary Healthcare February 1, 2023 Paul Cardle, Saravana Kumar, M. Leach et al.

Background Chronic musculoskeletal pain (CMSP) disorders are a leading cause of disability globally, affecting up to one in three people. Mindfulness-based interventions (MBI) have become a popular treatment for CMSP. The aim of this umbrella review was to synthesise the best available research evidence for the effectiveness of MBI for adults with CMSP. Methods Eight databases were searched...

Consumer Experiences with Delta-8-THC: Medical Use, Pharmaceutical Substitution, and Comparisons with Delta-9-THC

Cannabis and Cannabinoid Research February 1, 2023 Daniel J. Kruger, Jessica S Kruger

Introduction: Cannabis products containing delta-8-THC became widely available in most of the United States in late 2020 and rapidly became a significant source of revenue for hemp processing companies, especially in states where use of delta-9-THC remains illegal or requires professional authorization for medical use. Scientific research on the use of delta-8-THC is scarce, previous clinical...

Translational Challenges in Psychedelic Medicine.

New England Journal of Medicine February 1, 2023 Robin Carhart-Harris 10 citations

A “nonpsychedelic psychedelic” compound was shown to have anxiolytic and antidepressive effects in a mouse model. This commentary asks whether assumptions implicit in mouse modeling can be trusted to translate to humans.

DOI: 10.1056/nejmcibr2213109 (opens in new tab) Psychedelic therapy Psychedelic treatments Psychedelic medicine Hallucinogenic treatments +15

Subacute effects of a single dose of psilocybin on biomarkers of inflammation in healthy humans: An open-label preliminary investigation.

Comprehensive Psychoneuroendocrinology February 1, 2023 Daniel Rødbro Burmester, Martin Korsbak Madsen, Attila Szabo et al. 24 citations

Psilocybin is a serotonergic psychedelic that has gained prominent attention recently as a potential therapeutic for neuropsychiatric disorders including Major Depressive Disorder. Pre-clinical and initial studies in humans suggest that serotonin 2A receptor agonists, including serotonergic psychedelics, have anti-inflammatory effects. This may contribute to its therapeutic effects as previous...